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Abstract
Tramadol is a complex drug, being metabolized by polymorphic enzymes and admin-
istered as a racemate with the (+)‐ and (−)‐enantiomers of the parent compound
and metabolites showing different pharmacological effects. The study aimed to
simultaneously determine the enantiomer concentrations of tramadol, O‐desmethyl-
tramadol, N‐desmethyltramadol, and N,O‐didesmethyltramadol following a single
dose, and elucidate if enantioselective pharmacokinetics is associated with the time
following drug intake and if interindividual differences may be genetically explained.
Nineteen healthy volunteers were orally administered either 50 or 100 mg tramadol,
whereupon blood samples were drawn at 17 occasions. Enantiomer concentrations
in whole blood were measured by LC‐MS/MS and the CYP2D6, CYP2B6 and CYP3A4
genotype were determined, using the xTAG CYP2D6 Kit, pyrosequencing and real‐
time PCR, respectively. A positive correlation between the (+)/(−)‐enantiomer ratio
and time following drug administration was shown for all four enantiomer pairs. The
largest increase in enantiomer ratio was observed for N‐desmethyltramadol in
CYP2D6 extensive and intermediate metabolizers, rising from about two to almost
seven during 24 hours following drug intake. CYP2D6 poor metabolizers showed
metabolic profiles markedly different from the ones of intermediate and extensive
metabolizers, with large area under the concentration curves (AUCs) of the N‐des-
methyltramadol enantiomers and low corresponding values of the O‐desmethyltra-
madol and N,O‐didesmethyltramadol enantiomers, especially of the (+)‐enantiomers.
Homozygosity of CYP2B6 *5 and *6 indicated a reduced enzyme function, although
further studies are required to confirm it. In conclusion, the increase in enantiomer
ratios over time might possibly be used to distinguish a recent tramadol intake from
a past one. It also implies that, even though (+)‐O‐desmethyltramadol is regarded
the enantiomer most potent in causing adverse effects, one should not investigate
Abbreviations: AUC, area under the concentration curve; DRS, drug-related symptoms; EM, extensive metabolizer; IM, intermediate metabolizer; LOQ, limit of quantification; NDT, N-
desmethyltramadol; NODT, N,O-didesmethyltramadol; ODT, O-desmethyltramadol; PM, poor metabolizer; QCs, quality controls; RQCs, ratio quality controls; UM, ultrarapid metabolizer.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2018 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for
Pharmacology and Experimental Therapeutics.
Received: 5 June 2018 | Accepted: 10 June 2018
DOI: 10.1002/prp2.419
Pharmacol Res Perspect. 2018;e00419.
https://doi.org/10.1002/prp2.419
wileyonlinelibrary.com/journal/prp2 | 1 of 10
the (+)/(−)‐enantiomer ratio of O‐desmethyltramadol in relation to side effects with-
out consideration for the time that has passed since drug intake.
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1 | INTRODUCTION
Tramadol is a relatively weak opioid with a dual mechanism of
action, acting both as a μ‐opioid receptor agonist and a neurotrans-
mitter reuptake inhibitor. Tramadol is administered as a racemate,
with the (+)‐ and (−)‐enantiomers of the parent compound and their
metabolites showing different pharmacological effects that synergis-
tically accomplish pain relief.1 The (+)‐enantiomer of tramadol is
most potent in inhibiting serotonin reuptake, while (−)‐tramadol pref-
erentially inhibits noradrenaline reuptake.2 The (+)‐enantiomer of the
metabolite O‐desmethyltramadol (ODT) is, however, exerting most of
the opioid effects, having the highest affinity and highest potency to
the μ‐opioid receptors.3 The general interpretation of previously per-
formed and published studies on humans is that (+)‐ODT is the
enantiomer most potent in relieving pain as well as in causing
adverse effects.4 The tramadol enantiomers have, however, been
proposed to cause adverse effects related to abuse and overdose of
the drug.5 The CYP2D6 enzyme is accountable for the formation of
ODT (Figure 1). Individuals may be classified as poor (PMs), interme-
diate (IMs), extensive (normal) (EMs) or ultrarapid metabolizers (UMs)
according to the metabolic activity of the CYP2D6 enzyme, deter-
mined by either phenotyping or predicted from genotyping. Several
studies have consistently showed that PMs, in comparison to EMs,
have an increased exposure to (+)‐ and (−)‐tramadol combined with
a reduced formation of especially (+)‐ODT but also of (−)‐ODT.
UMs, on the contrary, are expected to form higher amounts of (+)‐
ODT than EMs and to be more prone to opioid‐related adverse
effects.4 Comparisons between EMs and UMs are, however, sparse
in scientific literature. Apart from ODT, there are two additional pri-
mary tramadol metabolites, N‐desmethyltramadol (NDT), and N,O‐
didesmethyltramadol (NODT) (Figure 1). NDT is pharmacologically
inactive, while NODT may exert some opioid effects.3 Formation of
NDT is mediated by the CYP2B6 and CYP3A4 enzyme, whereas the
metabolism route of NODT is less assured. However, all three
enzymes; CYP2D6, CYP2B6, and CYP3A4 are candidates (Figure 1).6
The CYP2B6 gene, in similarity with CYP2D6, is highly polymorphic
although less studied. The significance of CYP2B6 polymorphisms in
tramadol pharmacokinetics and pharmacodynamics has not yet been
investigated. Nevertheless, both increased and decreased expression
and activity of the enzyme as a result of genetic variation have been
observed for other substrates.7 For CYP3A4, there is substantial
interindividual variation in expression and function. Many polymor-
phisms have been identified in the CYP3A4 gene, although most of
them have not been associated with the phenotypical variability.8
However, studies indicate that CYP3A4*22 results in reduced
enzyme activity, as demonstrated in vivo with the CYP3A4 probe
drugs midazolam and erythromycin,9 and is affecting the pharma-
cokinetics and pharmacodynamics of several drugs.10-12
To better understand the pharmacological and adverse effects of
tramadol, its metabolism and the influence of genetic polymor-
phisms, the use of enantioselective analytical methods and genotyp-
ing are of importance in studies of tramadol. Only two of the
tramadol sterioisomers are administered as the racemic drug; the
enantiomeric pair of 1R,2R (+) and 1S,2S (−).13 Tramadol and its
three main metabolites thus give rise to four pairs of enantiomers in
the blood following drug intake. To our knowledge, all eight com-
pounds have not been simultaneously determined in a study popula-
tion earlier. The overall aim of the present study was therefore to
obtain such metabolic profiles in healthy volunteers receiving a sin-
gle, therapeutic dose of tramadol. The enantioselective method
needed for conducting such a study has previously been developed
and validated.14 Specifically, the following research questions and
hypotheses were posted:
1 Can interindividual differences in enantioselective metabolic pro-
files be explained by CYP2D6, CYP2B6, and/or CYP3A4 genotype?
The hypothesis is that interindividual differences are better
explained by the combined genotype of all three enzymes
involved in the metabolism of the drug, rather than by CYP2D6
itself.
2 Is there a correlation between (+)/(−)-enantiomer ratios of tra-
madol or its metabolites and time following drug administration?
To our knowledge, this has not been investigated in a study pop-
ulation previously, although there are indicators of such a relation
in literature. Rudaz et al. showed that enantiomer ratios of all four
compounds in urine changed over time in one individual adminis-
tered 100 mg tramadol.15
2 | MATERIALS AND METHODS
2.1 | Study population
The present study was based on analysis of blood samples collected
in conjunction to a previous survey.16 Nineteen healthy volunteers
aged between 19 and 34 years (median 25), were randomized into
two groups, administered a single dose of either 50 or 100 mg tra-
madol as an oral immediate‐release formulation (Tramadol HEXAL,
Sandoz). Blood samples were drawn from a peripheral venous cathe-
ter in the forearm at 17 occasions; prior to dosing and at 0.5, 1, 1.5,
2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 24, 48, and 72 hours after
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administration. The tubes contained sodium fluoride and potassium
oxalate. Two aliquots of each blood sample were stored at −80°C
pending nonchiral16 and chiral analysis of tramadol and its metabo-
lites, respectively.
The participants were not allowed to undergo any drug treat-
ment, with the exception of contraceptive medication, which was
used by seven subjects. However, one participant (subject 04),
reported intake of an antihistamine about 12.5 hours before the tra-
madol administration. In conjunction to the last blood sampling on
the first day (10 hours), the subjects were requested to fill in a form
regarding their experience of drug‐related symptoms (DRS). The par-
ticipants were asked to grade their experiences of nausea, dizziness,
headache, vomiting, dry mouth, sweating, fatigue, and any other
DRS on a scale between zero to five, where zero was no symptoms
at all and five was the worst imaginable symptoms. The study was
approved by the Regional Ethical Review Board in Linköping (No:
2011/337‐31), and written informed consent was gathered from the
participants.
2.2 | Pharmacokinetic assessments
The enantioselective analysis of tramadol, ODT, NDT, and NODT in
whole blood was performed at the National Board of Forensic Medi-
cine in Linköping, Sweden, using a validated LC‐MS/MS‐method that
has been described in detail previously.14 In brief, blood samples of
0.5 g were fortified with an internal standard consisting of tra-
madol‐13C‐D3 and O‐desmethyl‐cis‐tramadol‐D6, followed by liquid–
liquid extraction at pH 11. The LC‐MS/MS‐method operated in the
reversed phase mode, using a chiral alpha‐1‐acid glycoprotein (AGP)
column preceded by an AGP guard column. The mobile phase con-
sisted of 0.8% acetonitrile and 99.2% ammonium acetate (20 mmol/
L, pH 7.2). A postcolumn infusion with 0.05% formic acid in acetoni-
trile was used to enhance sensitivity. The calibration curve of each
substance covered an enantiomer concentration range of 0.25‐
250 ng/g. The limit of quantification (LOQ) was 0.125 ng/g for all
enantiomers except for (+)‐ and (−)‐ODT with a corresponding limit
of 0.50 ng/g. Historical calibration was utilized for the calculation of
sample concentrations. All blood samples drawn from the same indi-
vidual were analyzed in a separate run, together with at least four
quality controls covering both enantiomeric quantitation (QCs) and
enantiomeric ratio quantitation (RQCs). QCs were prepared from
racemic reference compounds at enantiomer concentrations of 1 ng/
g and 200 ng/g for all eight compounds. The QCs were not allowed
to deviate from the nominal value with more than ±20% for approval
of the run in question. The RQCs were prepared from pure enan-
tiomeric reference compounds, in (+)/(−)‐enantiomer ratios of 0.25
and 4.0, respectively. The area ratio between the (+)‐ and (−)‐enan-
tiomers in the RQCs was not allowed to deviate from the median
area ratio obtained in the validation process with more than ±8%
(two standard deviations). Long‐term stability tests at a low (1 ng/g)
and a high (200 ng/g) enantiomer concentration were performed in
−80°C up to 24 months. The difference in mean concentration
between the stability samples and the fresh control samples at
24 months was in the range of −6% to −11% at the low concentra-
tion level and 0.5%‐5% at the high concentration level. The prede-
termined limit of acceptance was ±25%.
2.3 | Genetic assessments
Genomic DNA was extracted using the Arrow Blood DNA 500 μL
kit (DiaSorin, Saluggia, Italy) and a NorDiag Arrow instrument (Auto-
gen, Holliston, MA). The DNA samples were stored at −20°C pend-
ing analysis. Genotyping was performed at the National Board of
Forensic Medicine in Linköping, Sweden and at Erasmus University
Medical Center in Rotterdam, The Netherlands.
For CYP2D6, gene multiplication and 15 alleles were investigated;
*2 (−1584 C > G, 1661 G > C, 2850 C > T, 4180 G > C), *3
(2549delA), *4 (100 C > T, 1661 G > C, 1846 G > A, 2850 C > T,
4180 G > C), *5 (whole‐gene deletion), *6 (1707delT, 4180 G > C),
*7 (2935 A > C), *8 (1661 G > C, 1758 G > T, 2850 C > T,
4180 G > C), *9 (2613delAGA), *10 (100 C > T, 1661 G > C,
4180 G > C), *11 (883 G > C, 1661 G > C, 2850 C > T, 4180 G > C),
F IGURE 1 Tramadol metabolism. Three
main metabolites are formed; O‐
desmethyltramadol (ODT), N‐
desmethyltramadol (NDT), and N,O‐
didesmethyltramadol (NODT) by the
CYP2D6, CYP2B6, and CYP3A4 enzymes.
Asterisks indicate the two chiral centers
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*15 (137_138insT), *17 (1023 C > T, 1661 G > C, 2850 C > T,
4180 G > C), *29 (1659 G > A, 1661 G > C, 2850 C > T, 3183 G > A,
4180 G > C), *35 (−1584 C > G, 31 G > A, 1661 G > C, 2850 C > T,
4180 G > C), *41 (1661 G > C, 2850 C > T, 2988 G > A, 4180 G > C),
using the FDA approved xTAG CYP2D6 Kit v3 (Luminex, Austin,
TX). Allele *3, *4, *5 and *6, as well as gene multiplication have
been investigated also previously, using pyrosequencing technol-
ogy.16 There were no discrepancies between the two different
methodologies used. There is no true consensus on how to perform
the classification of certain genotypes into phenotypes.4,17,18 In the
present study, the guidelines of the Dutch Pharmacogenetics Work-
ing Group (DPWG) were used, which are also internationally recog-
nized (www.pharmgkb.org), have been published, and which are used
for dose recommendations.19 Consequently, individuals with two
functional CYP2D6 alleles or one functional and one decreased func-
tional allele were classified as EMs, individuals with one nonfunc-
tional allele and one functional or decreased functional allele as IMs
and individuals with two nonfunctional alleles as PMs. UMs were
defined as individuals with CYP2D6 multiplications, resulting in at
least three functional CYP2D6 alleles.
Pyrosequencing technology was utilized for the CYP2B6 genotyp-
ing. Three polymorphisms were identified in the CYP2B6 gene;
516 G > T (rs3745274), 785 A > G (rs2279343) and 1459 C > T
(rs3211371), making it possible to determine allele *4 (785 A > G),
*5 (1459 C > T), *6 (516 G > T and 785 A > G), *7 (516 G > T, 785
A > G and 1459 C > T) and *9 (516 G > T). Amplification of the
extracted DNA was performed in a total volume of 10 μL consisting
of 5 μL HotStarTaq Plus Master Mix (Qiagen, Hilden, Germany),
3.6 μL RNase‐free water (Qiagen), 0.2 μL of the forward and reverse
primer (Invitrogen, Lidingö, Sweden) in a concentration of 20 μmol/L
and 1 μL of genomic DNA in a concentration of at least 30 ng/μL.
The polymerase chain reaction (PCR) was initialized at 95°C for
5 minutes, followed by 40 cycles of denaturation at 95°C for 30 sec-
onds, annealing at 50°C (516 G > T) or 58°C (785 A > G and 1459
C > T) for 30 seconds and extension at 72°C for 30 seconds. Final
elongation was performed at 72°C for 10 minutes before the reac-
tion was finalized at 4°C. Pyrosequencing was performed as previ-
ously described,16 using the primer sequences and dispensation
orders given in Falk et al.20 For CYP3A4*22, Taqman analysis was
used as described earlier.21 Alleles without any of the investigated
polymorphisms were designated as functional wild-type alleles (*1).
2.4 | Pharmacokinetic and statistical calculations
Pharmacokinetic and genetic assessments were successfully per-
formed in the blood samples of all participants. However, concerning
five participants, blood samples could not be obtained at all 17 time
points. From four of the individuals, there was one blood sample
that could not be drawn, and from one individual there were three
samples missing. This was due to different reasons, for example, a
not properly working peripheral venous catheter.
Cmax was defined as the maximum measured concentration and
tmax the time when Cmax was achieved. Other pharmacokinetic
parameters were calculated in Microsoft Excel 2013, the area under
the concentration curve (AUC) by using the linear trapezoidal
method. Log‐transformed concentrations in the elimination phase
were used to determine the elimination rate constant, and subse-
quently t1/2 and the extrapolated area between the time of the last
measured concentration above LOQ and infinity. The extrapolated
area of one or several compounds exceeded 20% of the total AUC
in five individuals. From the subject showing the highest extrapo-
lated areas, between 24% and 50% for all eight compounds, blood
samples could not be drawn past 10 hours. The other four individu-
als presented extrapolated areas exceeding 20% regarding one or
two compounds, the highest value being 27%.
Two statistical calculations, with a significance level of 0.05, were
performed to elucidate the most appropriate approach for data pre-
sentation. Regarding the dose‐dependent parameters AUC and Cmax, a
two‐tailed Wilcoxon rank‐sum test did not show any statistically signif-
icant difference between the 50 mg dosage group when obtained val-
ues were multiplied by two, and the 100 mg dosage group, indicating
linear pharmacokinetics. Therefore, AUC values were dose-adjusted to
100 mg prior to the establishment of Figure 3 and 4. A two‐tailed
Wilcoxon rank‐sum test was also used to compare the enantiomer
concentration ratios between the 50 and 100 mg dosage group at all
time points. No statistically significant difference was detected. Conse-
quently, the enantiomer ratios in Figure 5 are presented without dis-
tinction between the two dosage groups. Otherwise, no statistical
tests were utilized, due to the relatively small sample size, and the
results are instead descriptively presented. However, a two‐tailed Wil-
coxon rank‐sum test with Bonferroni correction was used to compare
the AUC values of tramadol in CYP2D6 EMs, IMs and PMs. The sta-
tistical tests were performed in MATLAB R2017b.
3 | RESULTS
3.1 | Metabolic profiles
The mean concentration vs time curves for the enantiomers of tra-
madol and its three main metabolites are shown in Figure 2. The
pharmacokinetic parameters AUC, Cmax, tmax and t1/2 are given in
Table 1, where wide ranges implicated large interindividual differ-
ences. Those differences are further depicted in Figure 3, showing
the dose‐adjusted, individual AUC of all four enantiomer pairs, ter-
med metabolic profiles.
The metabolic profiles of the two CYP2D6 PMs, subject 05 and
19, were markedly different compared to the ones of individuals
with other CYP2D6 phenotypes (Figure 3). They were characterized
by large AUCs of the NDT enantiomers, with concomitant small
AUCs of the ODT and NODT enantiomers. The (+)‐enantiomers of
ODT and NODT were affected to a larger extent than the (−)‐enan-
tiomers. Subject 05, administered the 50 mg dose, never achieved
(+)‐ODT or (+)‐NODT concentration levels above LOQ. Concentra-
tions above LOQ of the NODT enantiomers in the two PMs were
low and constituted more of a plateau over time than a curve. Total
AUC and t1/2 could therefore not be calculated. On group‐level, both
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PMs and IMs showed larger AUCs of the tramadol enantiomers com-
pared to the EMs (Figure 3), with P‐values ranging from 0.021 to
0.044. However, the differences were not statistically significant
after correction for multiple comparisons, since significance then
required a P‐value below 0.017.
In the subjects not being CYP2D6 PMs, ODT was the major
metabolite with AUCs larger than that of the NDT and NODT enan-
tiomers (Figure 3). Three CYP2D6 IMs, however, constituted an
exception, most prominent in subject 16. This individual showed lar-
ger AUCs of both the NDT and NODT enantiomers than of the
F IGURE 2 Mean enantiomer
concentration versus time of tramadol and
its three main metabolites following a
single, oral dose of either 50 mg (n = 10)
or 100 mg (n = 9). Only concentrations
above the limit of quantification (LOQ)
were included in the analysis, and the
mean values presented are based on at
least three individual observations
TABLE 1 Pharmacokinetic parameters of the enantiomers of tramadol and its three main metabolites O‐desmethyltramadol (ODT), N‐
desmethyltramadol (NDT), and N,O‐didesmethyltramadol (NODT), following an oral, single dose of either 50 mg (n = 10) or 100 mg (n = 9)
50 mg 100 mg
Mean Median Range Mean Median Range
(+) (−) (+) (−) (+) (−) (+) (−) (+) (−) (+) (−)
Tramadol
AUC (ng/g*h) 786 668 775 631 537‐1192 440‐1124 1784 1501 1810 1526 1242‐2288 993‐2129
Cmax (ng/g) 82 75 82 73 64‐110 57‐96 176 160 176 159 134‐208 117‐190
tmax (h) 2.5 2.3 2.6 2.4 1.6‐3.1 1.6‐2.6 2.7 2.6 3.0 3.0 1.5‐3.7 1.5‐3.7
t1/2 (h) 5.8 5.4 5.3 4.9 4.5‐8.0 4.2‐7.4 6.0 5.4 5.9 5.5 4.6‐7.4 3.9‐7.1
ODT
AUC (ng/g*h) 225a 222 253a 222 154‐353a 113‐330 420 408 456 447 65‐697 208‐656
Cmax (ng/g) 19 19 19 23 13‐23 5‐24 28 33 34 31 4‐51 14‐59
tmax (h) 3.3 2.9 3.1 2.6 2.6‐4.1 2.1‐4.1 3.5 2.9 3.5 3.2 2.1‐5.1 1.6‐4.1
t1/2 (h) 6.8
a 6.5 6.8a 6.0 5.8‐8.3a 4.3‐10.3 7.9 6.9 7.3 7.2 5.9‐10.6 5.3‐9.4
NDT
AUC (ng/g*h) 293 99 128 36 46‐1812 13‐698 700 194 324 84 145‐2569 44‐857
Cmax (ng/g) 12 5 10 4 4‐33 2‐14 30 12 31 10 11‐60 5‐30
tmax (h) 5.4 3.5 3.6 2.6 2.6‐23.9 2.1‐10.1 5.5 3.8 4.1 3.6 1.5‐10.3 1.5‐8.1
t1/2 (h) 8.1 6.2 6.5 4.9 5.8‐21.7 2.9‐17.8 8.2 6.1 7.4 5.7 4.8‐18.5 3.8‐10.8
NODT
AUC (ng/g*h) 105a 112a 107a 115a 69‐164a 68‐149a 270a 264a 283a 270a 131‐352a 152‐369a
Cmax (ng/g) 7 8 7 8 4‐11 0.7‐13 13 16 13 16 0.3‐25 5‐27
tmax (h) 4.2 5.3 3.6 2.9 2.6‐8.1 2.6‐23.9 6.1 5.0 5.3 4.1 3.5‐10.3 1.5‐10.3
t1/2 (h) 7.7
a 6.7a 7.5a 6.3a 6.6‐9.2a 5.3‐8.5a 7.7a 6.7a 7.9a 6.6a 5.8‐9.8a 5.0‐8.8a
aIndicate that the results of the CYP2D6 poor metabolizers were excluded, since values were below LOQ or could not be calculated.
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ODT enantiomers. Subject 16 did also report the highest DRS score
(which has been fully declared previously16), and did both faint (at
1 hour and 15 minutes following drug intake) and vomit (at about
4 hours following drug administration and also later in the evening)
during the experimental day. Subject 16 carried one decreased func-
tional CYP2D6 allele and one nonfunctional CYP2D6 allele (Table 2).
Large AUCs of the ODT enantiomers in relation to the AUCs of
the tramadol enantiomers were shown in subject 18 and 03 (Fig-
ure 3). The AUC (+)‐ODT/(+)‐tramadol ratio in those individuals was
0.56 and 0.47, respectively, with a mean value in the whole group of
0.30. The AUC (−)‐ODT/(−)‐tramadol ratio was 0.66 and 0.71,
respectively, with a mean ratio of 0.33. Subject 18 was a CYP2D6
EM with CYP2B6 genotype *1/*5 and CYP3A4 genotype *1/*22. Sub-
ject 03 was a CYP2D6 IM with no other of the investigated poly-
morphisms detected (Table 2).
Two other individuals, subject 02 and 14, showed metabolic pro-
files consisting of the smallest AUCs of the NDT enantiomers and,
with the exception of the CYP2D6 PMs, the smallest AUCs of the
NODT enantiomers (Figure 3). Both individuals were CYP2D6 EMs
with the CYP2B6 genotype *6/*6 and *5/*5, respectively (Table 2).
The differences in metabolic profiles of those two subjects compared
to the other CYP2D6 EMs are further illustrated in Figure 4. Regard-
ing both NDT and NODT, the mean AUC of the variant
homozygotes was reduced by approximately 50% compared to the
wild-type homozygotes and the heterozygotes. Subject 06, being a
CYP2D6 IM with the CYP2B6 *6/*6 genotype did, however, not
show the same marked difference in metabolic profile.
3.2 | Correlation between enantiomer ratios and
time following drug administration
Positive correlations were found when the mean (+)/(−)‐enantiomer
ratios of tramadol and its main metabolites were plotted against time
after drug intake in CYP2D6 PMs, IMs, and EMs (Figure 5). The cor-
relations of tramadol and NDT were close to linear during 24 hours,
while there was a change in linearity for ODT and NODT. The enan-
tiomer ratios of tramadol were similar in all genotype groups, while
the CYP2D6 PMs showed markedly lower ratios and also a smaller
increase in enantiomer ratio over time regarding the metabolites.
Concerning NODT, the PM did not show any change at all in enan-
tiomer ratio. One of the CYP2D6 IMs differed from the others by
having notably lower (+)/(−)‐enantiomer ratios of ODT and NODT,
ratios that placed themselves between the IM and PM group (Data
S1). This individual, subject 16, carried a nonfunctional allele in com-
bination with a decreased functional one, while the other IMs carried
one nonfunctional and one functional allele. The largest increase in
F IGURE 3 Metabolic profiles showing the total area under the concentration curve (AUC) of the enantiomers of tramadol and its three
main metabolites in individuals with different CYP2D6 phenotypes and CYP2B6 genotypes. Participants were orally administered either 50 or
100 mg tramadol, however, the present values were dose‐adjusted to 100 mg since linear pharmacokinetics was shown. EMs = extensive
metabolizers, IMs = intermediate metabolizers, PMs = poor metabolizers, M = major (wild-type) allele, m = minor (variant) allele
6 of 10 | HAAGE ET AL.
enantiomer ratio over time was seen for NDT, with about three
times increase in enantiomer ratio over 24 hours for the CYP2D6
EMs and IMs. However, in conformity with the results of the other
pharmacokinetic parameters, there were large interindividual differ-
ences (Data S1).
4 | DISCUSSION
4.1 | Metabolic profiles
This study describes the enantioselective pharmacokinetics of tra-
madol and its three main metabolites simultaneously. Previously,
only less numerous enantiomer pairs have been studied concurrently.
The observed mean and median values of AUC, Cmax, tmax , and t1/2
regarding tramadol, ODT, and NDT are in accordance with previous
studies that also administered a single, oral dose of 5022 and
100 mg.22-25 However, data available in literature reflects the phar-
macokinetics in plasma and serum, while the present study presents
the pharmacokinetics in whole blood. Enantiomeric pharmacokinetic
parameters of NODT have previously only been reported following a
200 mg extended‐release formulation.26
Great interindividual differences in drug exposure were apparent,
illustrated by the metabolic profiles of the four enantiomer pairs
(Figure 3). Two CYP2D6 PMs participated in the present study,
showing metabolic profiles different from the others. Conspicuously
large AUCs of the NDT enantiomers and low corresponding values
of the ODT and NODT enantiomers were shown. The (+)‐
enantiomers of ODT and NODT were affected to a larger extent
than the (−)‐enantiomers. Those results are in line with previous
publications, showing that PMs, in comparison to EMs, achieve a
decreased AUC of mainly (+)‐ODT but also of (−)‐ODT 22,25,27 and
an increased AUC of the NDT enantiomers.25 However, enantiose-
lective measurements of NODT have not, to our knowledge, been
performed in different CYP2D6 phenotype groups previously. Con-
sidering the tramadol metabolism scheme (Figure 1), the observed
reduced levels of the NODT enantiomers were expected. NODT is
formed from both ODT and NDT. Since PMs only form low amounts
of ODT due to the abolished function of CYP2D6, most NODT will
be formed from NDT. It is proposed that the enzyme metabolizing
NDT to NODT is also CYP2D6, for what reason only low concentra-
tions of NODT, and especially of (+)‐NODT, are expected to be
formed. As a consequence, the amounts of the NDT enantiomers
will accumulate. Earlier studies have also shown that PMs achieve an
increased AUC of both (+)‐ and (−)‐tramadol,22,25,27 and the present
one indicated that both CYP2D6 IMs and PMs achieved larger AUCs
of the tramadol enantiomers than the EMs.
Another metabolic profile that leapt out belonged to a CYP2D6
IM, the only one carrying a nonfunctional allele in combination with
a decreased functional one. The AUCs of both the NDT and NODT
enantiomers exceeded the ones of the ODT enantiomers. In accor-
dance with the CYP2D6 genotype, those results indicate a reduced,
but not abolished, CYP2D6 function. The same individual was the
one being mostly affected by the drug, both fainting and vomiting
during the experimental day. The general hypothesis in literature
regarding adverse effects following tramadol administration is that
the frequency and intensity is related to the concentrations of (+)‐
ODT. The higher the concentration, the higher risk of side effects
and toxicity.4,6 However, review authors have expressed a need of
more studies before a relationship between CYP2D6 metabolizer
status and tramadol adverse effects might be established.28,29 In the
present study, the individual experiencing most DRS was the one
TABLE 2 CYP2D6, CYP2B6, and CYP3A4 genotype of 19 healthy
volunteers administered either 50 or 100 mg tramadol
CYP2D6 phenotype Subject Dose CYP2D6 CYP2B6 CYP3A4
EM 17 100 *1/*9 *1/*1 *1/*1
EM 09 50 *1/*1 *1/*1 *1/*1
EM 08 50 *1/*41 *1/*1 *1/*1
EM 18 100 *2/*35 *1/*5 *1/*22
EM 01 50 *1/*2 *1/*5 *1/*1
EM 10 50 *2/*41 *1/*5 *1/*1
EM 14 100 *1/*35 *5/*5 *1/*1
EM 02 50 *1/*1 *6/*6 *1/*1
IM 11 100 *1/*5 *1/*1 *1/*1
IM 15 100 *1/*4 *1/*1 *1/*1
IM 12 100 *4/*35 *1/*1 *1/*1
IM 03 50 *1/*5 *1/*1 *1/*1
IM 07 50 *2/*5 *1/*1 *1/*1
IM 13 100 *1/*3 *1/*7 *1/*1
IM 16 100 *4/*41 *1/*6 *1/*1
IM 04 50 *1/*5 *1/*6 *1/*1
IM 06 50 *1/*4 *6/*6 *1/*1
PM 19 100 *4/*4 *1/*1 *1/*1
PM 05 50 *4/*5 *1/*1 *1/*1
F IGURE 4 Mean area under the concentration curves (AUCs) of
the enantiomers of tramadol and its three main metabolites in
CYP2D6 extensive metabolizers, having different CYP2B6 genotypes.
AUC values were dose-adjusted to 100 mg. M = major (wild-type)
allele, m = minor (variant) allele, TRA = Tramadol, ODT = O‐
desmethyltramadol, NDT = N‐desmethyltramadol, NODT = N,O‐
didesmethyltramadol
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with the second lowest Cmax and AUC of (+)‐ODT in the 100 mg
dosage group (only the PM individual showed lower values). How-
ever, DRS should probably better be examined among clinical
patients on tramadol treatment, than among healthy volunteers only
receiving a single, therapeutic dose.
Metabolic profiles with large AUCs of the ODT enantiomers in
relation to the AUCs of the tramadol enantiomers were shown in
two subjects, and could be expected in CYP2D6 UMs. However, the
current individuals were a CYP2D6 EM with CYP2B6 genotype *1/*5
and CYP3A4 genotype *1/*22, and a CYP2D6 IM, respectively. No
other individual in the present study carried the CYP3A4*22 allele,
an allele that has been associated with a decreased enzyme func-
tion.9 However, if a reduced N‐demethylation of tramadol, by indi-
rect means, had caused the increased O‐demethylation, a smaller
AUC of the NDT‐enantiomers might have been expected. Another
possible explanation for increased AUC of the ODT enantiomers,
although not investigated in the present study, is polymorphisms in
the SLC22A1 gene. The gene encodes a transporter named OCT1
that mediates reuptake of ODT in the liver. Polymorphisms resulting
in an inactive protein have been shown to cause increased AUCs of
(+)‐ODT and (−)‐ODT in healthy volunteers administered a single
oral dose of 100 mg.30
The significance of CYP2B6 polymorphisms in tramadol pharma-
cokinetics has not been carefully investigated. In a study that eluci-
dated potential genetic factors and covariates affecting the clearance
of (+)‐ and (−)‐tramadol in a group of neuropathic pain patients,
CYP2B6 *9 was not found to significantly contribute.31 In the pre-
sent study, the metabolic profiles with the smallest AUCs of the
NDT enantiomers belonged to two individuals being CYP2D6 EMs
with the CYP2B6 genotype *6/*6 and *5/*5, respectively. They also
showed small AUCs of the NODT enantiomers, only the PMs
showed lower values. However, a gene–dose relationship, which is
commonly shown for CYP enzymes, could not be demonstrated (Fig-
ure 4). Nevertheless, the difference, large or small, between wild-type
homozygotes and heterozygotes may be substrate dependent. Also,
regarding this particular pharmacokinetic parameter, not only
CYP2B6 but also CYP3A4, is expected to influence the outcome.
Herein, the CYP2D6 IM with the CYP2B6 *6/*6 genotype did not
show the same pronounced difference in metabolic profile, which
further underlines the need of additional studies on this subject.
4.2 | Correlation between enantiomer ratios and
time following drug administration
A positive correlation between the (+)/(−)‐enantiomer ratio and time
following drug administration was found regarding all four enan-
tiomer pairs. If further investigated in a larger population, also taking
different dosages, regular dosing and drug interactions into consider-
ation, enantiomer ratios could potentially be used to estimate the
time of tramadol intake, or with less nicety, distinguish between a
recent or past administration. From a clinical and forensic perspec-
tive, that could, for instance, be helpful regarding patient adherence
to medical treatment and in drugs and driving cases, respectively.
However, from the present investigation, it is obvious that there are
large interindividual differences, which must also be carefully consid-
ered in further studies. Nevertheless, an advantage with the pro-
posed method is the possibility of combining the information of four
different enantiomer ratios, given that the CYP2D6 genotype is
known.
Both the tramadol and ODT enantiomers have been subjects of
discussion regarding adverse effects.4-6 It has been clarified that the
tramadol enantiomers have different pharmacological effects,
although it has not been examined if there is a difference also in
their ability to produce side effects. For ODT, it is the (+)‐
F IGURE 5 Correlation between the mean (+)/(−)‐enantiomer ratios of tramadol, O‐desmethyltramadol, N‐desmethyltramadol and N,O‐
didesmethyltramadol, and time in CYP2D6 poor (PMs), intermediate (IMs) and extensive metabolizers (EMs), respectively. The healthy
volunteers were administered an oral, single dose of either 50 or 100 mg tramadol. One of the two PMs never achieved concentrations of (+)‐
O‐desmethyltramadol or (+)‐N,O‐didesmethyltramadol above the limit of quantification, and subsequently enantiomer ratios could not be
calculated
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enantiomer that has been proposed to be most potent in causing
adverse effects. In further investigations on the subject, it might be
well worth knowing that the (+)/(−)‐enantiomer ratios increases with
the time following ingestion.
5 | CONCLUSIONS
The most significant finding of the study was that (+)/(−)‐enantiomer
ratios of tramadol and its three main metabolites were positively
correlated with the time following drug intake. If further investi-
gated, the ratios might be used to distinguish a recent drug intake
from a past one. Concerning the proposed association between con-
centrations of (+)‐ODT and the risk of adverse effects, it is impor-
tant knowing that the (+)/(−)‐enantiomer ratios of ODT are affected
not only by the CYP2D6 genotype, but also by the time that has
passed between drug administration and blood sampling. It was con-
firmed that CYP2D6 PMs show a metabolic profile significantly dif-
ferent from the ones of IMs and EMs. Considerably larger AUCs of
the NDT enantiomers were found, combined with much smaller, or
noncalculable, AUCs of the ODT and NODT enantiomers, especially
of the (+)‐enantiomers. Homozygosity of the CYP2B6 alleles *5 and
*6, not previously investigated regarding tramadol metabolism, indi-
cated a reduced enzyme function. However, this pilot finding needs
to be confirmed in a larger study population.
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